Palexia Retard (Tapentadol Hydrochloride)

Tapentadol hydrochloride, the active ingredient in Palexia Retard, is a centrally acting analgesic presented as a prolonged‑release formulation for oral use. It is indicated for the management of moderate to severe chronic pain in adult patients when other analgesics are insufficient. GNH USA supplies Palexia Retard as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Tapentadol is an opioid analgesic that acts on the nociceptive pain pathway to provide relief in several chronic pain conditions. - Chronic low back pain: helps reduce pain intensity and improve functional ability. - Osteoarthritis pain: alleviates persistent joint discomfort. - Neuropathic pain associated with diabetic peripheral neuropathy: lessens shooting and burning sensations. - Cancer‑related chronic pain: contributes to overall pain control as part of multimodal therapy.

Tapentadol may cause a range of adverse reactions, from mild to severe, that vary among patients.

Common Side Effects: - Nausea: mild to moderate upset stomach. - Constipation: reduced bowel movements. - Dizziness: feeling light‑headed or unsteady. - Somnolence: increased sleepiness. - Headache: mild to moderate head pain. - Dry mouth: reduced salivation.

Serious or Rare Side Effects: - Respiratory depression: slowed or shallow breathing. - Seizures: convulsive episodes, especially at high doses. - Severe hypotension: marked drop in blood pressure. - Serotonin syndrome: agitation, hyperthermia, tremor when combined with serotonergic agents. - Allergic reactions: rash, itching, swelling, or anaphylaxis. - Addiction or dependence: potential for misuse with prolonged use.

When prescribing Tapentadol, clinicians should evaluate patient history and monitor for safety concerns. - Assess renal and hepatic function: adjust dosing if impairment is present. - Review concomitant CNS depressants: increased risk of sedation and respiratory depression. - Monitor for signs of abuse or dependence: implement risk‑mitigation strategies. - Caution in patients with a history of seizures: may lower seizure threshold. - Avoid abrupt discontinuation: taper gradually to prevent withdrawal. - Store at ambient temperature: keep below 25 °C, in the original container, protected from moisture and light.

Tapentadol interacts with several drug classes; understanding the interaction potential helps prevent adverse events.

Major Interactions (Avoid): - MAO inhibitors: risk of hypertensive crisis or serotonin syndrome. - CNS depressants (benzodiazepines, barbiturates, alcohol): additive respiratory depression. - Serotonergic agents (SSRIs, SNRIs, tramadol): heightened risk of serotonin syndrome.

Moderate Interactions (Monitor Closely): - CYP2D6 inhibitors (fluoxetine, quinidine): may increase tapentadol plasma levels. - CYP3A4 inducers (rifampicin, carbamazepine): may reduce analgesic effectiveness. - Antihypertensives: additive hypotensive effect. - Diuretics: potential for enhanced orthostatic hypotension.